title: Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke.
abstract: Excess activation of ionotropic glutamate receptors, primarily N-methyl-D-aspartate (NMDA) receptors and free radicals, evoke nerve cell death following hypoxic-ischemic brain injury in various animal models. However, clinical trials in stroke patients using NMDA receptor antagonists have failed to show efficacy primarily due to the limited therapeutic time window for neuroprotection and a narrow therapeutic index. In comparison, antioxidants prolonged the time window for neuroprotection in animal models of ischemic stroke and showed greater therapeutic potential in clinical trials for ischemic stroke. Excess activation of NMDA receptors and free radicals mediate the two separate pathways of nerve cell death in stroke and a safe and multifunctional drug that can block both routes in the brain will likely provide a better therapeutic outcome in patients with stroke. Derivatives of the lead structures of sulfasalazine and aspirin have led to the discovery of a new molecule, Neu2000, that has demonstrated excellent neuroprotection against NMDA- and free radical-induced cell death. Neu2000 is an NR2B-selective, moderate NMDA receptor antagonist with potent cell-permeable, spin trapping antioxidant action even at nanomolar concentrations. Nonclinical and human phase I studies demonstrated that Neu2000 can be translated to treat patients with stroke with better efficacy and therapeutic time window.
authors.affiliation: Department of Neuroscience and Pharmacology, Ajou University, Suwon, Gyeonggido, South Korea.
authors.forename: Sung Ig
authors.initials: SI
authors.lastname: Cho
authors.forename: Ui Jin
authors.initials: UJ
authors.lastname: Park
authors.forename: Jun-Mo
authors.initials: JM
authors.lastname: Chung
authors.forename: Byoung Joo
authors.initials: BJ
authors.lastname: Gwag
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000009:adverse effects / Q000494:pharmacology*; D001565:Benzoates / Q000009:adverse effects / Q000494:pharmacology*; D002545:Brain Ischemia / Q000188:drug therapy / Q000503:physiopathology; D016503:Drug Delivery Systems; D005464:Fluorobenzenes; D006801:Humans; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000494:pharmacology; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D012459:Salicylates; D019097:Spin Trapping; D020521:Stroke / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors; D062368:meta-Aminobenzoates
chemical_list: C519903:2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)benzoic acid; D000975:Antioxidants; D001565:Benzoates; D005464:Fluorobenzenes; D018696:Neuroprotective Agents; D016194:Receptors, N-Methyl-D-Aspartate; D012459:Salicylates; D062368:meta-Aminobenzoates